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To the editor:
The interesting letter to the editor by Mecabo et al.1 sheds new perspective on the
correlation of lactate dehydrogenase (LDH) and hemolysis in patients with sickle
cell anemia (SCA). Their data show that LDH-3 seems to be the isoenzyme that is
correlated with hemolysis. Accordingly, LDH-3 could be a useful marker in future
studies to determine the source of elevated levels of serum LDH in patients with
SCA as well as in other diseases. Expense, insurance approval and clinical
availability, however, may hamper its availability on a routine basis. Moreover and
unlike previous reports,2,3 Mecabo et al.1 found that hydroxyurea (HU) did not
show reduction of LDH or other hemolytic parameters in patients with SCA taking
HU. Lactate dehydrogenase-3, however, was decreased in patients with SCA
taking HU.
Given the above new information, I wish to clarify two issues pertinent to this
controversial subject. Since sickle cell disease (SCD) is a hemolytic disorder, all its
variants have variable degrees of hemolysis and, hence, have variable degrees of
elevated LDH levels that are most severe in SS. In a subset of patients with SCA
and uncomplicated vaso-occlusive crises (VOC) a hyperhemolytic state was
characterized by 40% decrease in the mean red blood cell (RBC) t1/2 survival
determined by 51Cr method, 53% decrease in total cell life, 54% increase in the
destructive rate of RBC with a significant 58% increase in LDH and changes in
other parameters of hemolysis compared to steady state values.4 The mean or
median levels in patients with hemolysis or hyperhemolysis are usually < 1000
U/L.1,4 Levels of LDH > 1000 U/L suggest additional sources of the enzyme with
or without hemolysis or hyperhemolysis especially if other parameters of
hemolysis are absent. Such high levels of LDH could be a sign of co-existent
tissue damage due to SCA. Elevated levels of LDH are also known to be markers
of testicular germ cell tumors and of melanoma. 5 In stage 3 testicular cancer the
LDH value could be more than 10 times the upper limit of the reference range. 6
Moreover, in multiple myeloma (MM) a high level of LDH is a poor prognostic
sign despite the fact that hemolysis is not an issue in MM.7 Similarly, it would be
instructive to use the LDH values or, even better, the LDH-3 values to rate the
severity of hemolysis and the presence or absence of organ damage in SCD.
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The second issue pertains to the effect of HU on the hemolytic parameters in
patients with SCA. We have prospectively studied the erythropoietic activity in
patients with SCA before and after treatment with HU.8 Some of the patients were
enrolled in the double-blind placebo controlled trial of HU in patients with SCA
(also known as the MSH study) and others were enrolled in an open label study.
Determinants of erythropoietic activity included, among other things, hemoglobin
(Hb), mean corpuscular volume (MCV), reticulocyte count, Hb F, RBC survival by
the 51Cr method, RBC life span and RBC production/destruction rate. As shown in
Table 1 responders to HU showed significant increase in MCV, Hb F, RBC
survival, cell life and in the production/destruction rate and significant decrease in
the reticulocyte count. Non-responders to HU and the placebo group showed no
difference before and after HU therapy. Moreover there was positive significant
correlation between Hb F level and RBC survival. The study by Mecabo et al1 did
not analyze the hemolytic parameters in terms of clinical response to HU and of
Hb F level that, apparently, was not determined. Furthermore, the authors stated
that the hemolytic parameters in the HU group were not statistically different from
the SS group that did not receive HU. Accordingly, it seems that the majority of
the patients taking HU were nonresponders and that may explain why the trial have
failed to show the beneficial effects of HU on RBC survival.
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